IRIDEX Corporation
IRIX announced today that its China distributor has been awarded a
competitive tender for more than $620,000 in ophthalmology laser equipment to
fulfill a government program designed to provide advanced ophthalmology
solutions to patients across vast areas of China's rural regions.
Will Moore, IRIDEX President and CEO, said, "In China, like all countries,
diabetes and age-related eye diseases are rising at an alarming rate, causing
varying degrees of blindness and an accompanying cost to the healthcare system
and society. The Chinese government has developed a number of progressive
strategies to provide advanced healthcare technologies in the rural areas of
the country, including ophthalmic care. The logistics and cost of drug
treatments is prohibitive in many of these regions. Alternatively, IRIDEX
laser-based treatments are as effective as drugs in terms of outcomes, are
much less costly to a healthcare system, and are much easier to administer
from a logistics standpoint because they provide durable results following a
single treatment."
Moore added that the advances in laser-based therapies are also ushering in a
paradigm shift in the U.S. and European ophthalmology markets, including
diabetic macular edema (DME) and glaucoma treatments.
"The ability now to achieve durable results against the progression of DME and
glaucoma without harming healthy tissue poses an attractive option for
physicians and their patients facing the high costs and low compliance rates
associated with drug-only approaches," Moore said.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: NewsPress Releases
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in